Here's why the Race Oncology (ASX:RAC) share price is leaping higher

The Race Oncology share price is leaping higher in late morning trade after emerging from a trading halt. We take a closer look…

The Race Oncology Ltd (ASX: RAC) share price is gaining today, up 5% in late morning trade.

The ASX healthcare share entered a trading halt on Monday prior to disclosing the details of a capital raising, which it released this morning.

Race Oncology's primary focus is its cancer drug, Bisantrene. Bisantrene has been shown to inhibit overexpression of the fat mass and obesity associated (FTO) protein, linked to a wide range of cancers.

jump in asx share price represented by man leaping up from one wooden pillar to the next

Image source: Getty Images

What did Race Oncology report on its capital raising?

The Race Oncology share price is moving higher today after the company reported it had raised $5.4 million from institutional and sophisticated investors in an oversubscribed placement. The capital raise is not subject to shareholder approval.

Race will issue approximately 1.8 million new shares at $3.00 per share. The stock is currently trading for $3.22 per share.

The company also revealed that participants in the capital raising will get 1 attaching option (exercisable at $4.50 and expiring 16 May 2022) for every 20 new shares they subscribed to at no cost.

Existing shareholders are also eligible for the 1 bonus option per 20 shares they hold on a pro-rata non-renounceable basis. Race reported it wants to reward its loyal shareholders while also helping grow the company.

Race plans to use the new capital to help develop Bisantrene.

Commenting on the successful capital raising, Race's CEO, Phil Lynch said:

This new funding supports efforts to deliver outsized returns to shareholders via our Three Pillar strategy, where we are investigating Bisantrene as both a potential precision oncology agent, and as a heart-friendlier chemotherapeutic.

Daniel Tillett, Race's CSO added, "We believe that this raise will accelerate our plans and rewards our loyal shareholders."

The company said it expects the new shares and placement options will be allotted and issued by 14 May.

Race Oncology share price snapshot

It's been a truly stellar year for Race Oncology shareholders, with shares up 794% over the past 12 months. For some perspective, the All Ordinaries Index (ASX: XAO) has gained 34% over that same time.

Year-to-date the Race Oncology share price has continued to outperform, with shares up 66% so far in 2021.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »